Pharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management

• Published in: Terapevtic̆eskii arhiv Vol. 93; no. 8; pp. 841 - 852
• Main Authors: Bakulin, Igor G., Skalinskaya, Maria I., Maev, Igor V., Skazyvaeva, Ekaterina V., Zhuravleva, Mariia S., Gaikovaya, Larisa B., Bakulina, Natalia V., Ermakov, Aleksei I., Alekseenko, Ekaterina S., Ivanova, Kristina N., Solovev, Mikhail V.
• Format: Journal Article
• Language: Russian
• Published: "Consilium Medicum" Publishing house 15.08.2021
• Subjects: 5-aminosalicylates; biologic therapy; crohn’s disease; efficacy of inflammatory bowel diseases therapy; inflammatory bowel diseases; safety of inflammatory bowel diseases therapy; thiopurines; ulcerative colitis
• ISSN: 0040-3660; 2309-5342
• DOI: 10.26442/00403660.2021.08.200982

Treatment of inflammatory bowel diseases IBD (Crohns disease, ulcerative colitis) is aimed at achieving clinical, endoscopic and histological remission, minimizing surgical complications, and ensuring a normal quality of life. However, the use of medical treatment is potentially associated with various adverse events, among which infectious complications, malignant neoplasms, as well as myelotoxicity, hepatotoxicity, skin lesions and others. The risk of side effects depends on the type of drug therapy (5-aminosalicylates, thiopurines, biologicals, etc.), the duration of treatment, the presence of extra-intestinal manifestations, etc. The article provides an overview of data on both the effectiveness and frequency of various side effects of the main classes of drugs in IBD, presents methods of investigation which can predict the effectiveness and development of side effects, the implementation of which can be considered as a variant of personalized therapy in IBD.